Trial Profile
Study of ATEGE [antithymocyte globulin]-Fresenius induction in liver transplantation followed by tacrolimus weaning.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Tacrolimus (Primary) ; Methylprednisolone; Prednisone
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Acronyms ATEGE-LIVER
- 26 May 2009 Planned end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
- 26 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 20 Mar 2007 New trial record.